Compare AbCellera Biologics Inc (ABCL) vs Warner Music Group Corp (WMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Warner Music Group Corp — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while Warner Music Group Corp trades at $29.08 (market cap $14.83B). The key difference: Warner Music Group Corp is far larger — about 6.3× AbCellera Biologics Inc's market cap, and Warner Music Group Corp pays a 2.67% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WMG | |
|---|---|---|
Market Cap | $2.35B | $14.83B |
Sector | Health | Media |
52-Week High | $8.12 | $34.72 |
52-Week Low | $2.78 | $23.65 |
Enterprise Value | $1.99B | $19.03B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Warner Music Group (WMG) trades at $28.44, up 0.57% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.35, beating expectations, and announced the acquisition of Sureel AI to strengthen IP management. Financials show revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. Valuation ratios include a P/E of 32.62 and P/S of 2.01, with a consensus analyst price target of $40.40 indicating significant upside potential.
WMG presents a mixed outlook: strong analyst support (66.7% buy ratings) and strategic AI investments offer growth opportunities, but bearish technicals, declining net margins, and competitive pressures pose risks. The stock's current price near support at $27 suggests cautious investor sentiment, with earnings consistency and margin improvement key to unlocking upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
